key: cord-0299120-q5n35sp7
authors: Allicock, O. M.; Yolda-Carr, D.; Todd, J.; Wyllie, A. L.
title: Pooled RNA: extraction free testing of saliva for SARS-CoV-2 detection
date: 2022-01-17
journal: nan
DOI: 10.1101/2022.01.16.22269390
sha: 116107c0bfaaa142049d509b5651582a21054b66
doc_id: 299120
cord_uid: q5n35sp7

The key to limiting SARS-CoV-2 spread is to identify virus-infected individuals (both symptomatic and asymptomatic) and isolate them from the general population. Hence, routine weekly testing for SARS-CoV-2 in all asymptomatic (capturing both infected and non-infected) individuals is considered critical in situations where a large number of individuals congregate such as schools, prisons, aged care facilities and industrial workplaces. Such testing is hampered by operational issues such as cost, test availability, access to healthcare workers and throughput. We developed the SalivaDirect RT-qPCR assay to increase access to SARS-CoV-2 testing via a low-cost, streamlined protocol using self-collected saliva. To expand the single sample testing protocol, we explored multiple extraction-free pooled saliva testing workflows prior to testing with the SalivaDirect assay. A pool size of five, with or without heat inactivation at 65{degrees}C for 15 minutes prior to testing resulted in a positive agreement of 98% and 89%, respectively, and an increased Ct value shift of 1.37 and 1.99 as compared to individual testing of the positive clinical saliva specimens. Applying this shift in Ct value to 316 individual, sequentially collected, SARS-CoV-2 positive saliva specimen results reported from six clinical laboratories using the original SalivaDirect assay, 100% of the samples would have been detected (Ct value >45) had they been tested in the 1:5 pool strategy. The availability of multiple pooled testing workflows for laboratories can increase test turnaround time, permitting results in a more actionable time frame while minimizing testing costs and changes to laboratory operational flow.

SalivaDirect assay. A pool size of five, with or without heat inactivation at 65°C for 15 23 minutes prior to testing resulted in a positive agreement of 98% and 89%, respectively, 24 and an increased Ct value shift of 1.37 and 1.99 as compared to individual testing of the 25 positive clinical saliva specimens. Applying this shift in Ct value to 316 individual, 26 sequentially collected, SARS-CoV-2 positive saliva specimen results reported from six 27 clinical laboratories using the original SalivaDirect assay, 100% of the samples would 28 have been detected (Ct value >45) had they been tested in the 1:5 pool strategy. The 29 availability of multiple pooled testing workflows for laboratories can increase test 30 turnaround time, permitting results in a more actionable time frame while minimizing 31 testing costs and changes to laboratory operational flow. 32 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Introduction 33

During the emergence and spread of the SARS-CoV-2 virus in 2020, the majority of 34 testing for the virus was aimed at diagnosing COVID-19 (the disease that it causes) in 35 patients presenting with symptoms characteristic of COVID-19. An infected person may 36 develop COVID-19 disease symptoms 3 to 8 days post infection or may never develop 37 symptoms (asymptomatic) (1-3). However, asymptomatic individuals can be infectious, 38 carrying viral loads high enough to spread the virus to uninfected individuals. Soon 39 thereafter it became clear that to control the spread of SARS-CoV-2 infection, a two-40 pronged approach must be used in the general population to prevent viral spread from 41 infected asymptomatic individuals to the non-infected population. 42

The first prong involves utilisation of physical barriers (e.g. face masks) to minimize virus 43 spread via aerosols (4, 5). The second prong involves routine weekly testing for CoV-2 in all asymptomatic (capturing both infected and non-infected) individuals at high-45 risk for infection (6, 7) . Such testing is considered critical in situations where many 46 individuals congregate such as schools, prisons, aged care facilities and industrial 47 workplaces. Testing strategies rely on obtaining a respiratory tract specimen and an assay 48 for the presence of SARS-CoV-2 antigen or genome. 49

It is generally considered that molecular tests for viral genome are more sensitive than the 50 antigen tests; however, they can be costly, can take days to return results and can be hard 51 to scale for large population testing. Furthermore, for tests requiring a swab-based 52 respiratory tract specimen, these can be uncomfortable and difficult to obtain, especially 53 under weekly self-collected specimen protocols, deterring individuals from participating in 54 testing (8). Early in the pandemic response, saliva emerged as an alternative specimen for 55 SARS-CoV-2 testing and by 2021 it became apparent that a self-collected specimen could 56 obviate the disadvantages of respiratory tract swab specimens. Importantly, the clinical 57 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 sensitivities for SARS-CoV-2 detection were similar between respiratory tract swab and 58 saliva specimens(9). 59

To address some of the limitations of testing, SalivaDirect TM was developed as an open-60 source protocol wherein clinical laboratories could adopt a streamlined, easy-to-use, 61

inexpensive, scalable and flexible genomic (RT-qPCR) assay method for SARS-CoV-2 62 detection (10). Importantly the assay is based upon a simple self or observed saliva 63 collection protocol. The SalivaDirect TM assay was developed to simplify testing individual 64 saliva specimens; however, with the momentum around testing large-scale asymptomatic 65 populations (e.g. school students, faculty and staff) where SARS-CoV-2 prevalence is low, 66 in a cost-effective manner, a more scalable protocol is required for sustainable testing 67 programs. We therefore investigated higher throughput protocols, wherein saliva 68 specimens are pooled prior to testing with RT-qPCR. These pooled testing approaches 69 were evaluated for the clinical sensitivity of SARS-CoV-2 detection. 70

The use of de-identified saliva specimens from healthy or asymptomatic individuals was 73 approved by the Institutional Review Board of the Yale Human Research Protection 74 Program (Protocol ID. 2000028394) (11). Study participants were informed in writing about 75 the purpose and procedure of the study, and consented to study participation through the 76 act of providing the saliva sample; the requirement for written informed consent was 77 waived by the Institutional Review Board. Additionally, the Institutional Review Board of 78 the Yale Human Research Protection Program determined that the use of de-identified, 79 remnant COVID-19-positive clinical samples obtained from laboratory partners for the qPCR testing conducted in this study is not research involving human subjects (Protocol 81 ID: 2000028599) . 82 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101/2022.01.16.22269390 doi: medRxiv preprint

All de-identified saliva samples used in the current study were collected unsupplemented 85 into simple laboratory plastic tubes per the SalivaDirect protocol (12). All samples were 86 tested with the SalivaDirect assay(13) in our research laboratory to confirm SARS-CoV-2 87 status. Samples were stored at -80°C until further analysis. 88

To understand the effect of sample dilution by pooling, on clinical sensitivity, a total of 20 90 saliva specimens which previously tested positive with the modified CDC assay RT-qPCR 91 assay, with resulting cycle threshold (Ct) values between 22.98 and 39.43, were diluted 92 1:5, 1:10, and 1:20 with negative saliva specimens from healthcare workers(14). Undiluted 93 specimens and pools were tested with the standard SalivaDirect RT-qPCR assay. 94

After identifying the optimal pool size, we performed an initial workflow evaluation using 5 95 different pooled samples, each composed of a single SARS-CoV-2-positive saliva sample 96 pooled with 4 SARS-CoV-2-negative saliva samples, in a 1:5 dilution. To confirm our initial 97 workflow findings and assess the sensitivity of viral detection when pooling, 20 additional 98 pools (1 positive with 4 negative saliva specimens) were prepared and tested using the 99 five different workflows. 100

The five different saliva pooling workflows investigated in both the initial and confirmation 101 studies are depicted in Figure 1 . All saliva samples were thawed on ice prior to testing 102 and all samples were tested in duplicate. For workflows A and C (Figure 1a) , 50 µl of 103 each sample, (including the SARS-CoV-2-positive saliva) were pooled to 250 µL total 104 volume, followed by vigorous vortexing. For workflow A, 50 µl of the pooled sample was 105 tested following the standard SalivaDirect protocol(10). For workflow C the remaining 106 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101/2022.01.16.22269390 doi: medRxiv preprint sample was treated with 10 µl of proteinase K then heat inactivated before testing directly 107 without further treatment in the SalivaDirect RT-qPCR assay. Workflows B, D and E 108 ( Figure 1b) involved incubating individual non-pooled samples at 65ºC for 15 minutes 109 before combining 50 µl of each sample into pools of 5 pre-treated samples. For workflow 110 B, 50 µl of the pool of pre-treated samples was tested through the standard SalivaDirect 111 protocol. For workflow E, 10 µl of each of these pre-treated pools was removed and tested 112 with the SalivaDirect RT-qPCR assay without proteinase K treatment. Finally, for workflow 113 D, 10 µl of proteinase K was added to the remaining volume of the pre-treated pool then 114 heat inactivated before testing in the SalivaDirect RT-qPCR assay. 115 116

To evaluate the real-world potential loss of sensitivity on clinical samples with pooling, we 118 estimated the average change in Ct value for each pooled testing workflow using the 119 results from the 25-sample workflow confirmation study. We then estimated how the 120 change in Ct value would potentially impact assay sensitivity by applying the Δ Ct value 121 (with pooling) to real world SalivaDirect RT-qPCR SARS-CoV-2 testing results. Six SARS-122

CoV-2 testing sites around the U.S., all testing with the standard SalivaDirect TM protocol, 123 provided sequential testing results (Ct values for positive specimens) during August 2021 124 and to these values we applied the Δ Ct value that we estimated. 125

The correlation of Ct values between each workflow and the individual positive samples 127 was assessed using the Pearson correlation coefficient and represented graphically with 128 linear regression. The negative RT-PCR of the target gene was set at the Ct value of 45 129 for the statistical analysis. All statistical analyses were performed using GraphPad Prism 130 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101/2022.01.16.22269390 doi: medRxiv preprint version 9 (GraphPad Software, San Diego, CA). For the calculation of percent positive 131 agreement, samples are considered positive at Ct < 45. 132

Pooling sizes and workflow selection 134

We initially performed a limit of detection range-finding study to determine the impact of 135 sample dilution via pooling with the SalivaDirect RT-qPCR assay on detection sensitivities. 136

As pool size increased the resulting assay Ct values increased as well, generally in a 137 linear manner. The smallest change in Ct values (i.e. loss of assay sensitivity) of pooled 138 versus neat saliva was obtained with 1:5 pooling (1 positive and 4 negative saliva 139 samples). Thus a 1:5 pooling strategy was employed for workflow analysis. Our 140 preliminary results indicated that the SalivaDirect assay was able to detect SARS-CoV-2 141 in pooled saliva specimens with high virus loads, but additional testing was required to 142 optimize saliva pooling and processing workflows. 143 147 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10. 1101 /2022 Extrapolating from previous work (Watkins et al. 2021) , we selected 5 workflows 148 representing different pooling strategies. Initial analyses using 5 pools showed that 4 149 workflows (A-D) provided similar results for most of the pools (see Table S1 Table 1, Table S2 ). 163

We assessed the sensitivity of each workflow by comparing to see which workflow had 164 the smallest shift in Ct values between the undiluted sample processed with SalivaDirect 165 RT-qPCR assay and the workflow in question, and by comparing which workflow had 166 the smallest number of pools dropping below the sensitivity threshold (between Ct 40 to 167 45). When compared to undiluted samples processed with the standard SalivaDirect 168 assay, Workflows A and B provided the highest sensitivity (Figure 2) . Workflows A and 169 B resulted in 3 and 1 pool(s) with Ct increases to 40 and 45, respectively. In contrast, 170 workflows C and D demonstrated the lowest in clinical sensitivity, with loss in detection 171 in 8/25 and 10/25 pools processed by these workflows respectively. 172 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101/2022.01.16.22269390 doi: medRxiv preprint individual replicates), compared to the individual testing results using the standard 174 SalivaDirect protocol. Workflow B resulted in a 98% positive agreement (100% and 96% 175 for the replicates), compared to the individual testing results using the standard 176 SalivaDirect protocol (Figure 2a) . The positive agreement for workflows C and D were 177 less, with averages of 76% and 62%, respectively. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Widespread surveillance of asymptomatic individuals is one of the main methods of 199 controlling the spread of SARS-CoV-2. The pooling of samples before testing is a 200 resource-saving approach to increase testing capacity, especially for surveillance in a 201 population with a low infection rate (14) Surveillance programs for SARS-CoV-2 genomic testing in low prevalence populations 220 must be operationally pragmatic. First, they need to be cost-effective. Pooled testing 221 significantly reduces reagent costs, lab personnel cost, and lab resource needs. Second, 222 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101/2022.01.16.22269390 doi: medRxiv preprint these programs need to be easy to implement. Self-collection of a simple saliva specimen 223 obviates the need for healthcare workers to collect specimens and the associated 224 personal protective equipment. Third, programs should utilize existing resources for 225 sample collection. Self-collection of saliva can be performed anywhere and the resulting 226 specimen can be deposited at a drop site location (e.g. school or workplace entrance) 227 such that specimens from thousands of participants are collected in a parallel manner. 228

Pooling of specimens once received in the laboratory for testing should fit into established 229 laboratory accessioning and pre-analytic workflows. Finally, the end test results must 230 provide acceptable clinical sensitivities and specificities. We have shown that a saliva-231 based RNA-extraction-free pooled (1:5) SalivaDirect is a flexible extraction-free platform for RT-qPCR testing. For ease of 246 implementation and safety of lab personnel, multiple workflows (18) were developed for 247 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 the testing of individual samples. We sought to extend this level of flexibility for labs 248 seeking to offer pooled testing. We demonstrated that workflows A and B provide the best 249 assay sensitivity, with B providing a heat pre-treatment step for labs who require it by local 250

Environmental Health and Safety guidelines. Consequently, workflows A and B were 251 selected as the proposed approaches for pooling of the SalivaDirect test. 252

Overall, surveillance testing is not generally easy, requiring a pivot by traditionally clinical 253 diagnostic labs, especially when scalable protocols do not exist. Thus, when a decrease in 254 positive cases are observed, there is a psychological and practical desire to decrease 255 testing. However, these dips in COVID-19 cases can lead to a decrease in pandemic 256 preventative measures, which inevitably leads to disease resurgence. Additionally, with 257 the introduction of different variants of concern, the need for affordable and sustainable 258 mass testing strategies only becomes more urgent. Our findings suggest that combining 259 saliva with a practical pooling protocol will enable easier SARS-CoV-2 surveillance testing, workflow E (orange), 10 µl of each of these pre-treated pools was removed and tested 294 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10. 1101 /2022 with the SalivaDirect TM RT-qPCR assay without proteinase K treatment. Finally, for 295 workflow D (blue), 10 µl of proteinase K was added to the remaining volume of the pre-296 treated pool then heat inactivated before testing in the SalivaDirect TM RT-qPCR assay. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10. 1101 /2022 

Estimates of the rate of 319 infection and asymptomatic COVID-19 disease in a population sample from SE

Presumed 322 (protocols.io.btdnni5e)

Testing Capacity with Pooled Saliva Samples

Implementation of a 376 pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-377 12 schools and universities

Effective SARS-CoV-2 Surveillance Testing Using Pooled Saliva Limits Viral 381 Spread on a Residential College Campus

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Asymptomatic Carrier Transmission of COVID-19. JAMA 323:1406 -1407 3.Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial 324 undocumented infection facilitates the rapid dissemination of novel coronavirus 325 Hellewell J, Russell TW, Investigators S, Field Study T, Crick C-C, group CC-w, 334Beale R, Kelly G, Houlihan C, Nastouli E, Kucharski AJ. 2021. Estimating the 335 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 17, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted January 17, 2022. ; https://doi.org/10. 1101 /2022